{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:16:10Z","timestamp":1775841370933,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1124\/jpet.120.000012","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T18:15:12Z","timestamp":1594836912000},"page":"69-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["New Proline, Alanine, Serine Repeat Sequence for Pharmacokinetic Enhancement of Anti-VEGF Single-Domain Antibody"],"prefix":"10.1016","volume":"375","author":[{"given":"Farnaz","family":"Khodabakhsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morteza","family":"Salimian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ardavan","family":"Mehdizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Sadeq","family":"Khosravy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Vafabakhsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmira","family":"Karami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-4184","authenticated-orcid":false,"given":"Reza Ahangari","family":"Cohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.000012_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/1567201814666171120122352","article-title":"PASylation as a powerful technology for improving the pharmacokinetic properties of biopharmaceuticals","volume":"15","author":"Ahmadpour","year":"2018","journal-title":"Curr Drug Deliv"},{"key":"10.1124\/jpet.120.000012_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1124\/jpet.120.000012_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2019.06.030","article-title":"Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins","volume":"307","author":"Brandl","year":"2019","journal-title":"J Control Release"},{"key":"10.1124\/jpet.120.000012_bib4","first-page":"1217","article-title":"Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin","volume":"6","author":"Cohan","year":"2011","journal-title":"Int J Nanomedicine"},{"key":"10.1124\/jpet.120.000012_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/biot.201200295","article-title":"Book review: therapeutic proteins: strategies to modulate their plasma half\u2010lives","volume":"8","author":"Dingermann","year":"2013","journal-title":"Biotechnol J"},{"key":"10.1124\/jpet.120.000012_bib6","series-title":"MAbs","first-page":"9","article-title":"The therapeutic monoclonal antibody market","author":"Ecker","year":"2015"},{"key":"10.1124\/jpet.120.000012_bib7","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.bmc.2017.09.016","article-title":"Prospects of PASylation\u00ae for the design of protein and peptide therapeutics with extended half-life and enhanced action","volume":"26","author":"Gebauer","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.120.000012_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10930-017-9699-9","article-title":"Molecular design, expression and evaluation of PASylated human recombinant erythropoietin with enhanced functional properties","volume":"36","author":"Hedayati","year":"2017","journal-title":"Protein J"},{"key":"10.1124\/jpet.120.000012_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/ct700301q","article-title":"GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J Chem Theory Comput"},{"key":"10.1124\/jpet.120.000012_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/antib4030141","article-title":"Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended Nanobodies\u00ae","volume":"4","author":"Hoefman","year":"2015","journal-title":"Antibodies"},{"key":"10.1124\/jpet.120.000012_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fimmu.2018.00273","article-title":"Single-domain antibodies and the promise of modular targeting in cancer imaging and treatment","volume":"9","author":"Iezzi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.120.000012_bib12","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1080\/21691401.2017.1369426","article-title":"Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties","volume":"46","author":"Khodabakhsh","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1124\/jpet.120.000012_bib13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jcis.2006.02.003","article-title":"Electrophoretic mobility equation for protein with molecular shape and charge multipole effects","volume":"299","author":"Kim","year":"2006","journal-title":"J Colloid Interface Sci"},{"key":"10.1124\/jpet.120.000012_bib14","series-title":"Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives","author":"Kontermann","year":"2012"},{"key":"10.1124\/jpet.120.000012_bib15","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr Opin Biotechnol"},{"key":"10.1124\/jpet.120.000012_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejphar.2016.10.039","article-title":"Angiogenesis inhibitors as therapeutic agents in cancer: challenges and future directions","volume":"793","author":"Lin","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.120.000012_bib17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/17435889.3.5.703","article-title":"Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats","volume":"3","author":"Longmire","year":"2008","journal-title":"Nanomedicine (Lond)"},{"key":"10.1124\/jpet.120.000012_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ejpb.2011.10.017","article-title":"Design, modeling, and expression of erythropoietin cysteine analogs in Pichia pastoris: improvement of mean residence times and in vivo activities through cysteine-specific PEGylation","volume":"80","author":"Maleki","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1124\/jpet.120.000012_bib19","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2967\/jnumed.116.176784","article-title":"Tumor uptake of anti-CD20 Fabs depends on tumor perfusion","volume":"57","author":"Mendler","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1124\/jpet.120.000012_bib20","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1021\/mp5007147","article-title":"PASylation of murine leptin leads to extended plasma half-life and enhanced in vivo efficacy","volume":"12","author":"Morath","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.120.000012_bib21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"10.1124\/jpet.120.000012_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2015.10.038","article-title":"Extension of in vivo half-life of biologically active molecules by XTEN protein polymers","volume":"240","author":"Podust","year":"2016","journal-title":"J Control Release"},{"key":"10.1124\/jpet.120.000012_bib23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nprot.2010.5","article-title":"I-TASSER: a unified platform for automated protein structure and function prediction","volume":"5","author":"Roy","year":"2010","journal-title":"Nat Protoc"},{"key":"10.1124\/jpet.120.000012_bib24","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nbt.1588","article-title":"A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner","volume":"27","author":"Schellenberger","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.120.000012_bib25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzt023","article-title":"PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins","volume":"26","author":"Schlapschy","year":"2013","journal-title":"Protein Eng Des Sel"},{"key":"10.1124\/jpet.120.000012_bib26","series-title":"Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges","author":"Schmidt","year":"2013"},{"key":"10.1124\/jpet.120.000012_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/jpet.120.000012_bib28","unstructured":"Skerra A Theobald I and Schlapschy M (2013) Biological active proteins having increased in vivo and\/or in vitro stability. US Patent Number 8563521, United States Patent and Trademark Office."},{"key":"10.1124\/jpet.120.000012_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ebiom.2016.04.028","article-title":"Nanobodies as versatile tools to understand, diagnose, visualize and treat cancer","volume":"8","author":"Van Audenhove","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1124\/jpet.120.000012_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","article-title":"The preclinical pharmacology of the high affinity anti-IL-6R Nanobody\u00ae ALX-0061 supports its clinical development in rheumatoid arthritis","volume":"17","author":"Van Roy","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1124\/jpet.120.000012_bib31","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1021\/bc300066a","article-title":"Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol)","volume":"23","author":"Vugmeyster","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1124\/jpet.120.000012_bib32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000488087","article-title":"Anti-angiogenics: current situation and future perspectives","volume":"41","author":"Zirlik","year":"2018","journal-title":"Oncol Res Treat"},{"key":"10.1124\/jpet.120.000012_bib33","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00253-016-7944-3","article-title":"PASylation technology improves recombinant interferon-\u03b21b solubility, stability, and biological activity","volume":"101","author":"Zvonova","year":"2017","journal-title":"Appl Microbiol Biotechnol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.000012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:35:26Z","timestamp":1739964926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524270075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0022356524270075"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.000012","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Proline, Alanine, Serine Repeat Sequence for Pharmacokinetic Enhancement of Anti-VEGF Single-Domain Antibody","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.000012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}